CVRdatabase
Menu

NP Bioinnovation A/S

Public limited companyCVR 41598263SøborgActive

NP Bioinnovation A/S is a public limited company, based in Søborg, active in manufacture of pharmaceutical preparations, founded in 2020. Equity was negative at the end of 2026 (−DKK 5.4m). The company made a loss in both 2025 and 2026, most recently DKK 5.5m.

Follow
PDF reportCompare

Key figures · financial year 2026

Gross profitDKK 4.9m+15,098.6% vs. 2025
Net profit−DKK 5.5m−9,092% vs. 2025
Equity−DKK 5.4m−3,288.8% vs. 2025
Employees12latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2026 against 2025

  • The loss grew: from DKK 60,069 to DKK 5.5m (2025 → 2026).
  • Equity turned negative: −DKK 5.4m (2025 → 2026).

Management and owners, last 24 months

  • New in management: Peter Severin Bach (chair of the board, 10/01/2025) and Allan Traugott Wehnert (board member, 24/09/2025).
  • Stepped down: Christian Torben Hill-Madsen (board member, 10/01/2025) and Henrik Keller (board member, 24/09/2025).

Registrations, last 24 months

  • 02/02/2026: Moved to Vandtårnsvej 62A, 1. b, 2860 Søborg
  • 07/11/2025: Moved to Vandtårnsvej 62A, 1. e, 2860 Søborg
  • 10/03/2025: Industry changed to Manufacture of pharmaceutical preparations (212000)
  • 10/03/2025: Name changed from NP Communications A/S to NP Bioinnovation A/S
  • 13/01/2025: Moved to Dyrehavevej 3B, 2930 Klampenborg
  • 10/01/2025: Industry changed to Public relations and communication activities (733000)

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2021–2026 · amounts in DKK thousand

Equity and net profit

−DKK 6m−DKK 5m−DKK 4m−DKK 3m−DKK 2m−DKK 1mDKK 020212022202420252026
EquityNet profit
Financial figures for NP Bioinnovation A/S
20212022202420252026Change
Revenuenot statednot statednot statednot statednot stated–
Gross profit−14−8−59−324,854+15,098.6%
Operating profit (EBIT)–−8−80−59−5,362−9,042.2%
Profit before tax−805152−80−60−5,522−9,092%
Net profit−805152−80−60−5,522−9,092%
Total assets139662632008,482+4,146.6%
Equity−76537228168−5,354−3,288.8%
Liabilities90329353213,836+43,350.6%
Cash and cash equivalents342834045–
Average number of employees000011–

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2021, 2022, 2024, 2025, 2026: smaller companies may omit it, and we do not derive it from other figures. The register has no financial statements for 2023 (changed financial year or not filed).

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 1mDKK 0DKK 1mDKK 2mDKK 3mDKK 4mDKK 5m20212022202420252026
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2026 figures

  • Negative equity

    Equity was −DKK 5.4m at the end of 2026.

    How is this calculated?

    Equity in the latest annual report is below zero.

  • Loss for 3 years in a row

    Net result has been negative in 2024–2026.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

5 financial years
Annual reports for NP Bioinnovation A/S
Financial yearPeriodPublishedFigures forDocuments
202601/04/2025 – 31/03/202601/10/2026The companyPDF not statedXBRL
202501/04/2024 – 31/03/202501/10/2025The companyPDF not statedXBRL
202401/04/2023 – 31/03/202407/05/2024The companyPDFXBRL
202201/07/2021 – 30/06/202205/10/2023The companyPDFXBRL
202112/08/2020 – 31/12/202101/11/2022The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
0246810121407/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profitDKK 4.9mNo. 25 of 57
Better than 57% of the companies in the industry
Equity−DKK 5.4mNo. 50 of 59
Better than 16% of the companies in the industry
Number of employees12No. 28 of 59
Better than 53% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bnHere
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 13,874of 69,742
Better than 80%
No. 69,229of 69,964
Better than 1%
Same industry and fewer than 20 employees37 companies in the comparison
No. 8of 36
Better than 80%
No. 31of 37
Better than 17%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 8,878of 33,588
Better than 74%
No. 33,112of 33,687
Better than 2%
All companies of type A/S18,025 companies in the comparison
No. 12,094of 17,786
Better than 32%
No. 17,695of 18,024
Better than 2%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. NP Bioinnovation A/SDKK 4.9m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. NP Bioinnovation A/S−DKK 5.5m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. NP Bioinnovation A/S−DKK 5.4m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. NP Bioinnovation A/S12
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Nordicus Partners Corporation100%
NP Bioinnovation A/S

Management

4 active registrations

Executive management

Executive management at NP Bioinnovation A/S
NameRoleAppointed
Christian Torben Hill-MadsenDirector12/06/2023

Board of directors

Board of directors at NP Bioinnovation A/S
NameRoleAppointed
Henrik RoufBoard member16/11/2022
Peter Severin BachChair of the board10/01/2025
Allan Traugott WehnertBoard member24/09/2025
Auditor
Crowe Statsautoriseret Revisionsinteressentskab
Founders
Glæsner Holding ApS, Karma ApS
Former management (6)
Former management at NP Bioinnovation A/S
NameRoleAppointedResigned
Hans Martin DamDirector12/08/202013/04/2022
Tom Glæsner LarsenDirector12/08/202012/06/2023
Christian Torben Hill-MadsenChair of the board16/11/202211/06/2023
Tom Glæsner LarsenBoard member16/11/202212/06/2023
Christian Torben Hill-MadsenBoard member12/06/202310/01/2025
Henrik KellerBoard member12/06/202324/09/2025

Signing rule: Selskabet tegnes af en direktør eller af 2 bestyrelsesmedlemmer i forening.

Address and production units

1 active production units

Vandtårnsvej 62A
2860 Søborg

Gladsaxe Municipality · Postcode 2860

Other companies at the address (1)

Production units
Production unitAddressEmployeesP number
NP Bioinnovation A/SVandtårnsvej 62A, 1. b, 2860 Søborg121026162846

Purpose

Selskabets formål er at udvikle lægemidler og dermed beslægtet virksomhed.

The purpose is quoted from the register in Danish.

Changes year by year

51 registered events
20262 changesaccounts 1 · address 1
  • Annual report for 2026 published
  • Moved to Vandtårnsvej 62A, 1. b, 2860 Søborg
202512 changesaddress 2 · accounts 1 · management 4 · name 2 · industry 3
  • Moved to Vandtårnsvej 62A, 1. e, 2860 Søborg
  • Annual report for 2025 published
  • Allan Traugott Wehnert appointed board member
  • Henrik Keller stepped down as board member
  • Name changed from NP Communications A/S to NP Bioinnovation A/S
  • Industry changed to Manufacture of pharmaceutical preparations (212000)
  • Moved to Dyrehavevej 3B, 2930 Klampenborg
  • Name changed from Managementselskabet af 12.08.2020 A/S to NP Communications A/S
  • Industry changed to Public relations and communication activities (733000)
  • Peter Severin Bach appointed chair of the board
  • Christian Torben Hill-Madsen stepped down as board member
  • Industry changed to Investment on own account (649910)
20242 changesaddress 1 · accounts 1
  • Moved to Dyrehavevej 3B, 2930 Klampenborg
  • Annual report for 2024 published
202312 changesname 1 · accounts 1 · management 6 · ownership 4
  • Name changed from NORDICUS Partners A/S to Managementselskabet af 12.08.2020 A/S
  • Annual report for 2022 published
  • Henrik Keller appointed board member
  • Christian Torben Hill-Madsen appointed board member
  • Christian Torben Hill-Madsen appointed director
  • Tom Glæsner Larsen stepped down as board member
  • Tom Glæsner Larsen stepped down as director
  • Christian Torben Hill-Madsen stepped down as chair of the board
  • Nordicus Partners Corporation registered as owner (100%)
  • Henrik Rouf is no longer registered as owner
  • GK PARTNERS ApS is no longer registered as owner
  • BIO-CONVERT A/S is no longer registered as owner
202217 changesname 3 · capital 1 · management 4 · ownership 6 · accounts 1 · address 2
  • Name changed from NORDICUS Partners ApS to NORDICUS Partners A/S
  • Share capital changed from 40,000 DKK to 400,000 DKK
  • Christian Torben Hill-Madsen appointed chair of the board
  • Henrik Rouf appointed board member
  • Tom Glæsner Larsen appointed board member
  • Henrik Rouf registered as owner (10%)
  • GK PARTNERS ApS registered as owner (66.67%)
  • BIO-CONVERT A/S registered as owner (5%)
  • GK PARTNERS ApS is no longer registered as owner
  • Annual report for 2021 published
  • Name changed from GK Consult ApS to NORDICUS Partners ApS
  • Moved to Dyrehavevej 3B, 2930 Klampenborg
  • Moved to Dyrehavevej 3, st, 2930 Klampenborg
  • Name changed from Glæsner & Dam ApS to GK Consult ApS
  • Hans Martin Dam stepped down as director
  • GK PARTNERS ApS registered as owner (100%)
  • KARMA ApS is no longer registered as owner
20211 changeownership 1
  • Glæsner Holding ApS is no longer registered as owner
20205 changesfounded 1 · management 2 · ownership 2
  • Registered as Glæsner & Dam ApS
  • Hans Martin Dam appointed director
  • Tom Glæsner Larsen appointed director
  • Glæsner Holding ApS registered as owner (50%)
  • KARMA ApS registered as owner (50%)

Related companies

Same industry in Gladsaxe

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction